COST

1,032.86

+0.16%↑

KO

80.16

-0.22%↓

PG

143.19

-0.03%↓

PM

189.34

+0.68%↑

PEP

149.47

-1.2%↓

COST

1,032.86

+0.16%↑

KO

80.16

-0.22%↓

PG

143.19

-0.03%↓

PM

189.34

+0.68%↑

PEP

149.47

-1.2%↓

COST

1,032.86

+0.16%↑

KO

80.16

-0.22%↓

PG

143.19

-0.03%↓

PM

189.34

+0.68%↑

PEP

149.47

-1.2%↓

COST

1,032.86

+0.16%↑

KO

80.16

-0.22%↓

PG

143.19

-0.03%↓

PM

189.34

+0.68%↑

PEP

149.47

-1.2%↓

COST

1,032.86

+0.16%↑

KO

80.16

-0.22%↓

PG

143.19

-0.03%↓

PM

189.34

+0.68%↑

PEP

149.47

-1.2%↓

Search

Lifecore Biomedical Inc

Geschlossen

BrancheKonsumgüter defensiv

4.5 -1.32

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.41

Max

4.59

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.9M

-6M

Verkäufe

-5.3M

31M

Gewinnspanne

-19.435

Angestellte

382

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+46.27% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-92M

149M

Vorheriger Eröffnungskurs

5.82

Vorheriger Schlusskurs

4.5

Nachrichtenstimmung

By Acuity

50%

50%

67 / 131 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Mai 2026, 22:54 UTC

Ergebnisse

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13. Mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13. Mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Mai 2026, 23:17 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13. Mai 2026, 23:16 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13. Mai 2026, 23:15 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13. Mai 2026, 23:14 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13. Mai 2026, 23:02 UTC

Market Talk
Ergebnisse

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13. Mai 2026, 22:59 UTC

Market Talk
Ergebnisse

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13. Mai 2026, 22:24 UTC

Ergebnisse

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Organic Revenue Growth 25%>XRO.AU

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Revenue Growth 47%>XRO.AU

13. Mai 2026, 22:22 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13. Mai 2026, 22:18 UTC

Ergebnisse

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13. Mai 2026, 22:16 UTC

Ergebnisse

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13. Mai 2026, 22:13 UTC

Ergebnisse

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13. Mai 2026, 22:12 UTC

Ergebnisse

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero Did Not Declare a Dividend>XRO.AU

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13. Mai 2026, 22:09 UTC

Ergebnisse

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13. Mai 2026, 22:00 UTC

Ergebnisse

Cisco to Shed Jobs for All-In AI Push -- Update

13. Mai 2026, 21:11 UTC

Ergebnisse

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer-Vergleich

Kursveränderung

Lifecore Biomedical Inc Prognose

Kursziel

By TipRanks

46.27% Vorteil

12-Monats-Prognose

Durchschnitt 6.67 USD  46.27%

Hoch 9 USD

Tief 5 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lifecore Biomedical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Stimmung

By Acuity

67 / 131 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
help-icon Live chat